Overview: C-KIT Mutation TestIntroduction: The C-KIT Mutation Test detects C-KIT gene mutations linked to cancers like gastrointestinal stromal tumors, causing abdominal pain. Following 2023 NCCN guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected cancers.
Other Names: C-KIT Gene Assay, GIST Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: C-KIT mutation testing began in the 2000s with GIST research. PCR-based assays emerged in the 2010s, improving diagnostic accuracy for targeted therapies.
Purpose: Diagnoses cancers like GIST, guides targeted therapy, and monitors C-KIT mutations in patients with abdominal pain.
Test Parameters: 1. C-KIT Mutation
Pretest Condition: No fasting required. Collect whole blood, bone marrow, tissue, or saliva at any time. Report symptoms like abdominal pain, and list medications like imatinib.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), 0.5-2 cma³ tissue (FFPE), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document abdominal pain, weight loss, or family history of GIST. Include current medications, especially targeted therapies like imatinib.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for targeted cancer therapy.
Procedural Considerations: Uses PCR to detect C-KIT mutations. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low sample quality or improper storage can reduce sensitivity. Contamination may cause false positives.
Clinical Significance: Positive C-KIT mutations confirm GIST, prompting imatinib therapy. Negative results suggest alternative diagnoses.
Specialist Consultation: Consult an oncologist for result interpretation. A gastroenterologist referral is advised for GIST cases.
Additional Supporting Tests: PDGFRA mutation test, abdominal CT, or biopsy to confirm GIST or assess disease extent.
Test Limitations: False negatives may occur with low mutation levels. Results require clinical correlation with pathology.
References: NCCN GIST Guidelines, 2023; Journal of Clinical Oncology, Demetri GD, 2022.
